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Non-microtubule components of mitosis, including polo-like kinase 
1 (PLK1), are required for complete cell division and have 
emerged as promising targets for cancer therapy. Human PLK1 is 
highly expressed in malignant lymphomas and acute myeloid 
leukaemia (AML), and elevated PLK1 is associated with poor 
prognosis in several cancer types (Liu et al, 2017) 
Several PLK inhibitors have shown anti-leukaemic activity 
in preclinical AML models (Hikichi et al, 2012; Munch et al, 2015; 
Rudolph et al, 2015; Rudolph et al, 2009; Valsasina et al, 2012), 
but published clinical experience in AML is limited to BI 2536 
(Müller-Tidow et al, 2013) and volasertib (Döhner et al, 2014). 
Volasertib is a potent, ATP-competitive and specific inhibitor of 
PLK1 and, to a lesser extent, the closely related kinases PLK2 
and PLK3 (Rudolph et al, 2009). It is the most advanced PLK 
inhibitor currently in clinical development. 
A combined phase I/II trial investigated volasertib in patient 
populations with AML who were ineligible for intensive treatment. 
The Phase II results, in patients with previously untreated AML, 
have been previously reported (Döhner et al, 2014). Here, we 
report the Phase I results, including maximum tolerated dose 
(MTD), safety, pharmacokinetics (PK) and anti-leukaemic activity, 
of intravenous volasertib as monotherapy or in combination with 
subcutaneous low-dose cytarabine (LDAC) in patients with 
relapsed/refractory AML considered ineligible for intensive 
treatment. 
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Patients were treated with escalating doses of volasertib 
(1-h intravenous infusion; starting dose 150 mg/infusion, escalated 
in 50 mg steps) on days 1 and 15 as monotherapy or in 
combination with fixed dose LDAC (2 x 20 mg/d subcutaneously 
on days 1–10) every 4 weeks. The study design is 
diagrammatically in Fig S1. All patients provided written informed 
consent. The trial was registered at ClinicalTrials.gov 
(NCT00804856). 
The primary objective was to determine the MTD for 
volasertib monotherapy and volasertib plus LDAC combination 
therapy. All analyses were descriptive and exploratory, and 
included patients receiving at least one dose of study drug 
(treated set). Full methodological details are in the Supporting 
Information. 
Eighty-eight adult patients with relapsed or refractory AML 
who were unsuitable for intensive salvage therapy were included 
between November 2008 and June 2012. Patient demographics 
and baseline disease characteristics are provided in Table S1. 
Fifty-six patients received volasertib monotherapy and thirty-two 
received volasertib plus LDAC combination therapy. Median age 
was 70 years (range, 26–84) in the monotherapy group and 71 
years (40–81) in the combination group. All patients had failed 
prior AML treatment and had received a median of 2 and 3 
previous anti-leukaemic therapy lines in the monotherapy and 
combination groups, respectively. 
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Dose escalations and dose-limiting toxicities are shown in 
Table I. For volasertib monotherapy, dose escalation was 
interrupted at 200 mg because of insufficient leukaemia control at 
the 150 mg and 200 mg dose and restarted from the MTD dose of 
350 mg determined in the volasertib + LDAC arm. The MTD was 
450 mg volasertib as monotherapy and 350 mg volasertib in 
combination with LDAC. An expansion cohort of 15 patients was 
treated with volasertib monotherapy at the 450 mg dose. 
Eighty-seven of 88 patients had discontinued treatment at 
the time of data analysis (data cut-off 07 November 2013), mostly 
due to disease progression (62·5%, both groups), while 20 
(22·7%) discontinued due to adverse events (AEs) (monotherapy, 
11 [19·6%]; combination, 9 [28·1%]). Sixteen deaths occurred 
while on study treatment or within 28 days of the last volasertib 
dose, three of which were suspected to be drug related: two with 
monotherapy (150 mg, cycle 1, fungal pneumonia; and 550 mg, 
cycle 1, pneumonia) and one with combination treatment (300 mg, 
cycle 1, pneumonia). Treatment-related AEs were reported in 38 
(67·9%) monotherapy patients and in 19 (59·4%) combination 
therapy patients. The most common treatment-related AEs were 
cytopenias and complications related to cytopenias. The most 
common grade ≥3 AEs are listed in Table II.  
Complete remission (CR)/CR with incomplete blood count 
recovery (CRi) was observed in 6 patients (18·8%) treated with 
combination therapy and 5 patients (8·9%) treated with 
monotherapy (Fig S2A). The duration of event-free survival 
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ranged from 153 to 392 days and from 64 to 566 days in the 
combination and monotherapy groups, respectively. CR or CRi 
was achieved after 1–3 treatment cycles in the combination group 
and after 1 treatment cycle in the monotherapy group. 
PK parameters are shown in Fig S3 and Table S2. 
Volasertib exposure was not affected by LDAC co-administration. 
For the pharmacodynamic analyses, a limited number of samples 
were evaluable due to technical limitations. An increase in the 
number of pH3-positive cells, mitotic catastrophe (mitotic arrest 
and subsequent apoptosis), and nuclear condensation and 
fragmentation, was clearly visible in evaluable bone marrow 
samples of volasertib-treated patients (Fig S2B).  
In this study, the safety profile of volasertib in this heavily 
pretreated population of AML patients was demonstrated as 
clinically manageable at doses above the recommended phase II 
dose (300 mg on day 1 of a 3-week treatment cycle) previously 
determined in solid tumour patients (Schöffski et al, 2012), and 
was consistent with the anti-mitotic mode of action of volasertib. 
PK parameters in this study were similar to those observed in 
other studies of volasertib (Schöffski et al, 2012; Stadler et al, 
2014). Pharmacodynamic activity was visible in the bone marrow 
1–5 days after volasertib administration with aberrant mitotic 
figures and characteristic nuclear condensation and fragmentation 
patterns, indicating that volasertib induces mitotic arrest and 
apoptosis in line with the clinical observation of blast reduction.  
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Volasertib alone or in combination with LDAC showed 
preliminary anti-leukaemic activity in patients with 
relapsed/refractory AML, a population with very limited therapeutic 
options. Based on these phase I results, the safety and efficacy of 
volasertib 350 mg plus LDAC versus LDAC alone has been further 
explored in the randomised phase IIa part of this trial (Döhner et 
al, 2014) and in an ongoing confirmatory phase III trial in the same 
patient population (POLO-AML-2; NCT01721876). 
Studies evaluating volasertib in AML and other 
haematological malignancies, particularly those determining the 
dose and schedule, should address the mechanisms of anti-
leukaemic activity, and its potential to augment efficacy of other 
agents by targeting PLK. 
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Table I. DLTs in cycle 1 and determination of MTD 
Dose level Patients, n Patients with 
DLTs, n 
DLTs 
Volasertib + LDAC (Schedule A) 
150 mg volasertib + LDAC 4 0 − 
200 mg volasertib + LDAC 3 0 − 
250 mg volasertib + LDAC 5 0 − 
300 mg volasertib + LDAC 9 1 Pneumonia 
350 mg volasertib + LDAC 8 1 Non-ST elevation myocardial 
infarction 
400 mg volasertib + LDAC 3 2 Mucosal inflammation (n = 1) 
Hypersensitivity (n = 1) 
Volasertib monotherapy (Schedule B) 
150 mg volasertib 11 1 Fungal pneumonia 
200 mg volasertib 2 0 − 
350 mg volasertib 5 0 − 
400 mg volasertib 6 1 Mucosal inflammation 
450 mg volasertib 23 1 Pyrexia 
500 mg volasertib 5 2 Thrombocytopenia and epistaxis 
(n = 1) 
Oesophagitis and GI 
inflammation (n = 1) 
550 mg volasertib 4 2 Mucosal inflammation (n = 1) 
Mucosal inflammation, GI 
haemorrhage, pneumonia, 
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haemoptysis, lung infiltration and 
dyspnoea (n = 1) 
DLT, dose-limiting toxicity; GI, gastrointestinal; LDAC, low-dose 
cytarabine; MTD, maximum tolerated dose 
*According to protocol, patients who were not evaluable for DLT 
(did not complete at least 1 cycle for reasons other than DLT) 
were replaced for determination of the MTD. Therefore, the patient 
number in some dose groups differs from 3 or 6. 
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Table II. Grade ≥3 adverse events by system organ class 
occurring in >10% of patients in a treatment group, with preferred 
term displayed if reported in ≥2 patients in a treatment group 
System organ class 
preferred term 
Volasertib  
n = 56  
n (%) 
Volasertib + LDAC 
n = 32  
n (%) 
Blood and lymphatic system disorders 
Thrombocytopenia 
Febrile neutropenia 
Anaemia 
Leukopenia 
Neutropenia 
Pancytopenia 
43 (76.8) 
26 (46.4) 
17 (30.4) 
20 (35.7) 
13 (23.2) 
22 (39.3) 
4 (7.1) 
23 (71.9) 
14 (43.8) 
13 (40.6) 
12 (37.5) 
10 (31.3) 
4 (12.5) 
− 
Cardiac disorders 
Cardiac failure 
2 (3.6) 
1 (1.8) 
4 (12.5) 
2 (6.3) 
Gastrointestinal disorders 
Diarrhoea 
8 (14.3) 
2 (3.6) 
4 (12.5) 
− 
General disorders and administration site conditions 
General physical health deterioration 
Pain 
Mucosal inflammation 
Oedema  
22 (39.3) 
13 (23.2) 
2 (3.6) 
6 (10.7) 
2 (3.6) 
10 (31.3) 
9 (28.1) 
2 (6.3) 
1 (3.1) 
− 
Infections and infestations 
Pneumonia fungal 
16 (28.6) 
1 (1.8) 
10 (31.3) 
4 (12.5) 
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Pneumonia 
Sepsis 
Infection 
9 (16.1) 
2 (3.6) 
2 (3.6) 
2 (6.3) 
2 (6.3) 
1 (3.1) 
Investigations 
C-reactive protein increased 
14 (25.0) 
9 (16.1) 
11 (34.4) 
8 (25.0) 
Metabolism and nutrition 
Hypokalaemia 
Hyperglycaemia 
Hypocalcaemia 
Decreased appetite 
Hyperuricaemia 
Hyponatraemia 
13 (23.2) 
6 (10.7) 
1 (1.8) 
3 (5.4) 
2 (3.6) 
2 (3.6) 
2 (3.6) 
10 (31.3) 
3 (9.4) 
3 (9.4) 
2 (6.3) 
1 (3.1) 
1 (3.1) 
− 
Respiratory, thoracic and mediastinal disorders 
Dyspnoea 
Epistaxis 
6 (10.7) 
5 (8.9) 
2 (3.6) 
4 (12.5) 
2 (6.3) 
1 (3.1) 
Vascular disorders 
Hypertension 
Hypertensive crisis 
4 (7.1) 
3 (5.4) 
− 
5 (15.6) 
2 (6.3) 
2 (6.3) 
LDAC, low-dose cytarabine 
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Supporting Information 
Methods 
Patients 
Adult patients with a confirmed diagnosis of acute myeloid 
leukaemia (AML) according to the World Health Organization 
2008 definition (Vardiman et al, 2009) whose disease had 
progressed on or following standard treatments and who were 
considered not suitable for intensive salvage therapy were eligible 
for this phase I study. All patients were required to have an 
Eastern Cooperative Oncology Group performance score ≤2 and 
adequate hepatic and renal function (bilirubin ≤1·5 mg/dl, 
aspartate aminotransferase/alanine transaminase ≤2·5 x upper 
limit of normal [ULN] or ≤5 x ULN in patients with leukaemia liver 
involvement; serum creatinine ≤2·0 mg/dl). Patients were 
excluded if they had acute promyelocytic leukaemia, another 
malignancy requiring treatment, symptomatic central nervous 
system leukaemia, clinically relevant QT prolongation, or other 
severe or uncontrollable medical conditions which would 
compromise evaluation of safety or efficacy based on medical 
judgment by the investigator. 
This study was conducted according to the guidelines of 
the Declaration of Helsinki, the International Conference on 
Harmonization-Good Clinical Practice and local legislation. Written 
informed consent was obtained from all patients. The trial was 
registered at ClinicalTrials.gov; registration number: 
NCT00804856. 
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Study design and patient enrolment 
The primary objective of this open-label, multicentre, phase I study 
was to determine the maximum tolerated dose (MTD) for 2 
treatment schedules, based on the number of patients with dose 
limiting toxicities (DLTs) in cycle 1: volasertib in combination with 
low-dose cytarabine (LDAC) and volasertib monotherapy. 
Secondary endpoints for phase I included incidence and grade of 
adverse events (AEs),the pharmacokinetic (PK) profile of 
volasertib when administered alone and in combination with LDAC 
and PK of LDAC after a single dose when given in combination 
with volasertib, pharmacodynamic monitoring for drug effect on 
leukaemia cells and event-free survival. 
The study design is depicted in Fig S1. In the phase I part, 
patients eligible for study entry were assigned to 1 of 2 treatment 
schedules. Schedule A patients received volasertib on days 1 and 
15 (1h intravenous infusion) combined with LDAC (2 x 20 mg/d 
subcutaneous) on days 1–10 of a 4-week treatment cycle while 
Schedule B patients received volasertib as monotherapy on days 
1 and 15 of a 4-week treatment cycle. Initially patients were 
recruited to Schedules A and B in parallel, but when the 200 mg 
dose in Schedule B was reached, recruitment was paused while 
Schedule A continued recruitment to reach the MTD. After 
determination of the MTD for Schedule A, recruitment in Schedule 
B was restarted at the MTD established in Schedule A. Dose 
escalation was conducted for each treatment group following a 
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3 + 3 design (Simon et al, 1997). The MTD was defined as the 
highest dose of volasertib at which 6 patients were treated and no 
more than 1 patient experienced DLT within the first cycle of 
treatment. Toxicities were graded according to the National 
Cancer Institute Common Terminology Criteria for Adverse Events 
(CTCAE; v.3.0). 
The criteria for DLTs were drug-related CTCAE grade ≥3 
non-haematological toxicity (excluding: untreated nausea, 
untreated vomiting, CTCAE grade 3 untreated diarrhoea, CTCAE 
grade 3 febrile neutropenia and CTCAE grade 3 infection with 
grade 3 or 4 neutrophils). For haematological toxicity, the DLT 
definition was restricted to patients achieving bone marrow blast 
clearance and included persistent drug-related CTCAE grade 4 
neutropenia or thrombocytopenia until 3 weeks after the end of the 
treatment cycle, unless the respective grade 4 cytopenia was pre-
existent. In patients who required platelet substitution to maintain 
a CTCAE grade <4 before treatment, a CTCAE grade 4 
thrombocytopenia after treatment did not constitute a DLT. 
Following MTD determination in the volasertib monotherapy arm 
(Schedule B) an additional 15 patients were evaluated for safety 
and efficacy in the MTD-expansion cohort. 
 
Treatment 
The starting dose of volasertib was 150 mg, with dose escalations 
in 50 mg steps. During the trial, no additional chemotherapy or 
immunotherapy was permitted, and prior anti-leukaemia 
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chemotherapy or immunotherapy had to be discontinued at least 2 
weeks before the first administration of volasertib; hydroxyurea 
could be given until 1 day before the first administration of the trial 
drug for peripheral blast control. 
Response to treatment was assessed at the end of each 
treatment cycle. Patients could continue treatment if there was no 
disease progression/relapse and if neutrophils were ≥500/μl (0·5 x 
109/l) and platelets ≥25 000/μl (25 x 109/l), unless grade 4 
neutropenia or thrombocytopenia was pre-existent. In the case of 
drug-related AEs preventing immediate continuation of treatment, 
further volasertib treatment was delayed until recovery from the 
AE. In the case of DLT, treatment was paused until recovery and 
restarted if the patient met criteria for further treatment with a 
reduced dose of volasertib for all subsequent treatment cycles 
(LDAC dose remained unchanged). Dose reduction of volasertib 
was allowed only once: treatment was permanently discontinued 
in patients experiencing a second DLT. An intrapatient dose 
escalation of volasertib (up to 50 mg/cycle) was permitted after the 
first cycle and in the absence of safety concerns to increase the 
probability of clinical benefit. 
 
Safety assessments 
Incidence of AEs was summarised by system organ class, 
severity, type and relation to study drug. Safety evaluations 
included assessment of haematological parameters, biochemistry 
panel assessment and urinalysis. At baseline, throughout 
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treatment and at the end of treatment electrocardiograms were 
recorded and cardiac enzyme assessments were performed. 
 
Efficacy assessments 
At screening, conventional cytogenetic and molecular genetic 
analyses were performed at a central reference laboratory. 
Genetic risk subgroups were defined according to the European 
LeukemiaNet (ELN) proposals (Döhner et al, 2010). Response 
was assessed in peripheral blood and bone marrow. Baseline 
bone marrow assessment was conducted within 2 weeks prior to 
the start of treatment. Bone marrow aspiration for response 
assessment was performed at the end of the first treatment cycle, 
and after subsequent treatment cycles if applicable. Responses 
were assessed at the trial site according to published criteria 
(Cheson et al, 2003; Döhner et al, 2010). 
 
Pharmacokinetics  
Blood samples for PK characterisation of volasertib and 
cytarabine were collected at pre-specified time points during the 
first and second cycles of volasertib monotherapy and 
combination treatment (cycle 1, day 1 before the start, 30 min 
after start and just before the end of the volasertib infusion, and 
then at 1·5, 2, 3, 4, 24, 96, 216 and 336 h after the start of 
infusion; cycle 1 day 15 before the start, 30 min after start and just 
before the end of the volasertib infusion, and then at 1·5, 2, 3, 4 
and 336 h after the start of infusion; cycle 2 day 1 before the start 
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and just before the end of the volasertib infusion). Plasma 
concentrations were determined by validated assays for volasertib 
(Awada et al, 2015) and cytarabine (Unpublished data, N. Plaud 
2011). The concentration–time data of volasertib and cytarabine in 
plasma were analyzed by non-compartmental methods, using the 
software WinNonlin® Professional (Pharsight Corporation, v5·02). 
 
Pharmacodynamics 
Bone marrow samples for pharmacodynamic evaluation were 
collected in cycle 1 before and 24–120 h after the first 
administration of volasertib and at the end of cycle 1. 
Pharmacodynamic analyses were performed to examine cell 
morphology, mitotic arrest and induction of apoptosis. After 
Ficoll™ gradient separation to obtain the mononuclear cell 
fraction, cells were centrifuged onto pre-coated microscope slides, 
and fixed in cold acetone/methanol. The percentage of cells 
arrested in mitosis was analysed by immunofluorescence labelling 
with phosphorylated histone H3 phosphoserine 10 (Upstate, Lake 
Placid, NY, USA) and α-tubulin (Sigma, St. Louis, MO, USA). 
Apoptosis was analysed by immunocytochemistry labelling for 
terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) (Chemicon International, Temecula, CA, USA). 
Cytological evaluation of bone marrow aspirates was performed 
by staining with May−Grünwald Giemsa. Microscopy pictures were 
obtained using an Axioskop 40 with 1000x magnification. 
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Statistical analysis 
All analyses were descriptive and exploratory by nature. Patients 
receiving at least 1 dose of study drug (treated set) were included 
in the analysis. Patients who had not completed at least 1 cycle 
for reasons other than DLT and were thus not evaluable for DLT 
were replaced in order to determine the MTD, but included in the 
treated set for all other analyses. 
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SUPPORTING FIGURES 
Fig S1. Study design: Phase I of a phase I/II trial assessing volasertib as monotherapy or in 
combination with cytarabine in AML (NCT00804856). 
 
AML, acute myeloid leukemia; LDAC, low-dose cytarabine; MTD, maximum tolerated dose; s.c., 
subcutaneous. 
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Fig S2. (A) Tumour response in the two treatment groups, and (B) bone marrow samples after 
the first volasertib infusion, showing an increase in the number of pH3-positive cells and a 
pattern of nuclear condensation and fragmentation that is characteristic of apoptosis following 
mitotic arrest by PLK inhibition (Polo-arrest) 
 
 
 
CR, complete remission; CRi, complete remission with incomplete blood count recovery; DAPI, 4',6-
diamidino-2-phenylindole; LDAC, low-dose cytarabine; PLK, polo like kinase;PR, partial response 
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Fig S3. Plasma concentration–time profile of volasertib following 1 h intravenous infusion of 150 
mg to 550 mg of volasertib in cycle 1 (first infusion at time 0 and second infusion at time 336 h). 
 
h, hours  
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SUPPORTING TABLES 
Table S1. Patient and disease characteristics. 
 Volasertib monotherapy  
(n=56) 
Volasertib + LDAC 
(n=32) 
Gender (male), % 27 (48.2) 21 (65.6) 
Age, years (median, range) 70 (26‒84) 71 (40–81) 
ECOG performance score, n (%)    
0 16 (28.6) 9 (28.1) 
1 31 (55.4) 18 (56.3) 
2 9 (16.1) 5 (15.6) 
WBC, 109/L (median, interquartile 
range) 
 3.7 (1.9−7.6)  3.1 (1.1−9.9) 
Secondary AML*, n (%) 20 (35.7) 13 (40.6) 
Gene mutations, n (%)   
NPM1 mutated 8 / 49 (16.3) 3 / 26 (11.5) 
NPM1 results missing 7 6 
FLT3-ITD 6 / 50 (12) 3 / 26 (11.5) 
FLT3-ITD results missing 6 6 
ELN genetic risk subgroup, n (%)   
Favourable 3 / 49 (6.1) 3 / 27 (11.1) 
Intermediate I/II 36 / 49 (73.5) 19 / 27 (70.4) 
Adverse 10 / 49 (20.4) 5 / 27 (18.5) 
Missing 7 5 
Previous systemic anti-leukaemic 
therapy lines (median, range) 
2 (1–5) 3 (1–13) 
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Patients with concomitant 
diagnosis,† n (%)  
  
Blood and lymphatic system 
disorders  
54/56 (96.4) 32/32 (100.0) 
Cardiac disorders  33/56 (58.9) 25/32 (78.1) 
Respiratory, thoracic and 
mediastinal disorders 
29/56 (51.8) 21/32 (65.6) 
Gastrointestinal disorders  35/56 (62.5) 23/32 (71.9) 
General disorders and 
administration site conditions  
43/56 (76.8) 22/32 (68.8) 
Hepatobiliary disorders  19/56 (33.9) 16/32 (50.0) 
Infections and infestations  39/56 (69.6) 18/32 (56.3) 
Investigations  38/56 (67.9) 27/32 (84.4) 
Metabolism and nutrition disorders 41/56 (73.2) 28/32 (87.5) 
Musculoskeletal and connective 
tissue disorders  
32/56 (57.1) 24/32 (75.0) 
Renal and urinary disorders  21/56 (37.5) 21/32 (65.6) 
Skin and subcutaneous tissue 
disorders  
28/56 (50.0) 19/32 (59.4) 
Surgical and medical procedures  29/56 (51.8) 19/32 (59.4) 
Vascular disorders  47/56 (83.9) 28/32 (87.5) 
*Defined as secondary to MDS or MPN. 
†By system organ class in ≥50% of patients in either treatment group  
AML, acute myeloid leukaemia; ECOG, Eastern Cooperative Oncology Group; ELN, European; 
ITD, internal tandem duplication; LeukemiaNet; LDAC, low-dose cytarabine MDS, 
myelodysplastic syndrome; MPN, myeloproliferative neoplasm; WBC, white blood cell count.
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Table S2. Non-compartmental PK parameters of volasertib monotherapy after intravenous infusion (1 h) on day 1 of cycle (Schedule 
B). 
PK parameters of 
volasertib 
150 mg 200 mg 350mg 400 mg 450 mg 500 mg 550 mg 
n gMean gCV 
[%] 
n gMean gCV 
[%] 
n gMean gCV 
[%] 
n gMean gCV 
[%] 
n gMean gCV 
[%] 
n gMean gCV 
[%] 
n gMean gCV 
[%] 
AUC0-∞ [ng·h/mL] 10 1880 29.3 − − − 5 7200 35.1 6 5980 62.1 22 8160 36.2 5 7320 38.5 3 9760 93.2 
AUC0-∞,norm 
[ng·h/mL/mg] 
10 12.5 29.3 − − − 5 20.6 35.1 6 14.9 62.1 22 18.1 36.2 5 14.6 38.5 3 17.7 93.2 
Cmax [ng/mL] 12 299 40.3 2 326 95.8 5 905 33.0 6 584 35.4 22 870 29.6 5 1190 35.0 4 867 55.6 
Cmax,norm 
[ng/mL/mg] 
12 2.00 40.3 2 1.63 95.8 5 2.59 33.0 6 1.46 35.4 22 1.93 29.6 5 2.38 35.0 4 1.45 61.2 
tmax [h]* 
12 0.542 
0.383 
–  
1.02 
2 0.484 
0.467 
– 
0.500 
5 0.933 
0.517 
– 
1.00 
6 0.934 
0.500 
–  
1.03 
22 0.909 
0.450 
–  
1.15 
5 0.917 
0.467  
–  
1.00 
4 1.21 
0.517 
–  
1.45 
t1/2 [h] 10 127 26.1 − − − 5 116 27.2 6 108 28.7 22 112 28.7 5 102 19.6 3 103 26.6 
MRT [h] 10 130 26.6 − − − 5 119 18.2 6 107 37.7 22 104 34.9 5 93.1 22.0 3 101 31.2 
CL [mL/min] 10 1330 29.3 − − − 5 810 35.1 6 1120 62.1 22 920 36.2 5 1140 38.5 3 939 93.2 
Vss [L] 10 10300 36.3 − − − 5 5800 35.1 6 7150 70.6 22 5740 38.7 5 6360 50.1 3 5680 81.9 
*Data are median and range (min–max) values. 
AUC0–∞, area under the plasma concentration–time curve from time zero to infinity; CL, total plasma clearance; Cmax, maximum 
measured concentration of the analyte in plasma; gCV, geometric coefficient of variance; gMean, geometric mean; MRT, mean 
residence time; PK, pharmacokinetic; norm, dose-normalized; tmax, the time at which Cmax is observed; t1/2, terminal half-life; Vss, 
apparent volume of distribution at steady state
  
31 
 
 
 
